Our Clinical Proteomics Team II is dedicated to in-depth research in the field of early lung cancer diagnosis. We have developed innovative proteomics pre-treatment methods based on microspheres and other cutting-edge technologies, specifically for analyzing body fluid samples. This study integrates multi-omics technologies, including proteomics, metabolomics, and radiomics, and combines them with bioinformatics and clinical research to provide a comprehensive and profound understanding of lung cancer. Through this interdisciplinary approach, we are committed to uncovering the complex mechanisms of lung cancer and advancing the development of early diagnostic techniques.